209 related articles for article (PubMed ID: 32730628)
21. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
[TBL] [Abstract][Full Text] [Related]
22. Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial.
Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Giorgio Masci P; Degrauwe S
Circulation; 2020 Dec; 142(25):2479-2481. PubMed ID: 33347326
[No Abstract] [Full Text] [Related]
23. Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial.
Fernando H; Duong T; Huynh K; Noonan J; Shaw J; Duffy SJ; Nehme Z; Smith K; Myles PS; Meikle PJ; Peter K; Stub D
Eur Heart J; 2021 Oct; 42(39):4025-4036. PubMed ID: 34423354
[TBL] [Abstract][Full Text] [Related]
24. Crushed/chewed administration of potent P2Y
Guo C; Zhao JR; Chen MJ; Zhang Y; Wu RY; Li QQ; Zhao H; Wei J
Platelets; 2022 Jul; 33(5):679-686. PubMed ID: 34472997
[TBL] [Abstract][Full Text] [Related]
25. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS
Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492
[TBL] [Abstract][Full Text] [Related]
26. Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
Vivas D; Jiménez JJ; Martín-Asenjo R; Bernardo E; Ortega-Pozzi MA; Gómez-Polo JC; Moreno G; Vilacosta I; Pérez-Villacastín J; Fernández-Ortiz A
J Thromb Thrombolysis; 2023 Feb; 55(2):203-210. PubMed ID: 36480147
[TBL] [Abstract][Full Text] [Related]
27. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP
J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336
[TBL] [Abstract][Full Text] [Related]
28. Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Jiang Z; Zhang R; Sun M; Liu Q; Wang S; Wang W; Zhao Q; Zhang H; Wang Y; Hou J; Yu B
Can J Cardiol; 2018 Dec; 34(12):1606-1612. PubMed ID: 30527148
[TBL] [Abstract][Full Text] [Related]
29. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study.
Montalescot G; Lassen JF; Hamm CW; Lapostolle F; Silvain J; ten Berg JM; Cantor WJ; Goodman SG; Licour M; Tsatsaris A; van't Hof AW
Am Heart J; 2013 Apr; 165(4):515-22. PubMed ID: 23537967
[TBL] [Abstract][Full Text] [Related]
30. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
31. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
Vlachojannis GJ; Vogel RF; Wilschut JM; Lemmert ME; Delewi R; Diletti R; van Vliet R; van der Waarden N; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
Am Heart J; 2020 Jun; 224():10-16. PubMed ID: 32272255
[TBL] [Abstract][Full Text] [Related]
32. Association of periprocedural intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: Systematic review and meta-analysis.
Batchelor R; Liu DH; Bloom J; Noaman S; Chan W
Catheter Cardiovasc Interv; 2020 Jul; 96(1):76-88. PubMed ID: 31654491
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis.
Vercellino M; Sànchez FA; Boasi V; Perri D; Tacchi C; Secco GG; Cattunar S; Pistis G; Mascelli G
BMC Cardiovasc Disord; 2017 Apr; 17(1):97. PubMed ID: 28381298
[TBL] [Abstract][Full Text] [Related]
34. Thrombogenicity and endothelial progenitor cells function during Acute myocardial infarction - comparison of Prasugrel versus Ticagrelor.
Wiessman M; Kheifets M; Schamroth Pravda N; Leshem Lev D; Ziv E; Kornowski R; Spectre G; Perl L
J Thromb Thrombolysis; 2023 Apr; 55(3):407-414. PubMed ID: 36598739
[TBL] [Abstract][Full Text] [Related]
35. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
36. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z; Zhou DY; Su Y; Si LY; Xu Q
BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
[TBL] [Abstract][Full Text] [Related]
37. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.
Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E
BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567
[TBL] [Abstract][Full Text] [Related]
38. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
39. Prehospital Prasugrel Versus Ticagrelor in Real-World Patients With ST-Elevation Myocardial Infarction Referred for Primary PCI: Procedural and 30-Day Outcomes.
Vos NS; Amoroso G; Vink MA; Maarse M; Adams R; Herrman JR; Patterson MS; van der Schaaf RJ; Slagboom T; de Winter RJ
J Invasive Cardiol; 2018 Dec; 30(12):431-436. PubMed ID: 30318484
[TBL] [Abstract][Full Text] [Related]
40. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
